Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT ID: NCT06071377
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2023-04-01
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Individuals with sickle cell trait
Biologic Specimen Collection
Participants will have blood and urine collected at Baseline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biologic Specimen Collection
Participants will have blood and urine collected at Baseline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Know/suspect they have SCT and are willing to get tested to confirm/learn about their SCT status
3. Adults ages 18 and older
Exclusion Criteria
2. Known end-stage renal disease or dialysis
3. Known SCD (including sickle cell-beta thalassemia)
4. People who do not have SCT
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beam Therapeutics Inc.
INDUSTRY
National Alliance for Sickle Cell Centers
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julie Kanter, MD
Role: PRINCIPAL_INVESTIGATOR
National Alliance for Sickle Cell Centers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Loma Linda University Health Care
Loma Linda, California, United States
Nemours Children's Hospital
Wilmington, Delaware, United States
Indiana University
Indianapolis, Indiana, United States
Functional Fluidics
Detroit, Michigan, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Duke University
Durham, North Carolina, United States
East Carolina University
Greenville, North Carolina, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
UT Health Houston
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marteesa William Oliver
Role: primary
Monica Pizana
Role: primary
Nicole Wittmeyer
Role: primary
Claire Kendrick
Role: primary
Jennell White, PhD
Role: primary
Ifeoma Iwuagwu
Role: backup
David Wichlan
Role: primary
Morgan Low
Role: primary
Sean Segre
Role: primary
Tiffany Rosetti
Role: primary
Amanda Gregg
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUNT
Identifier Type: -
Identifier Source: org_study_id